Eli Lilly has been having major wins since their earnings.
They’re drugs are no longer in shortage, Zepound was found to have cardiovascular benefits, and their once a week insulin is showing equal results to daily insulin injections.
The cardiovascular benefits from zepound is huge because patient insurances are more likely to cover drugs like this, without patients having to try other medications since it’s an actual benefit that no other fat loss meds have and it help lower the risk of their patients being in the hospital, which will save insurance companies more money at the end.
The weekly insulin is HUGE. The biggest complaints patients have is the amount of times they have to inject themselves throughout the day. The benefit this will have, is that both type 1 and type 2 diabetics can use this and there is a smaller risk of hypoglycemia/lower blood sugar since there’s no defined peak with the insulin.
I feel like this is the lowest $Eli Lilly(LLY)$ will get before it shoots up.
Comments